Last 12 months
Prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B
Qi Zheng, Biyao Zou, Yuankai Wu,Yeehui Yeo, Huizhen Wu, Christopher D Stave, Ramsey C. Cheung, Mindie H. Nguyen.
Approximately 30% of patients with CHB had HS, which was positively associated with male sex, diabetes and metabolic factors, and was negatively associated with HBeAg and HBV DNA. HS was not significantly associated with increased fibrosis.
Substantial gaps in evaluation and treatment of patients with hepatitis B in the US
Qing Ye, MD, Leslie Y. Kam, MD, Yee Hui Yeo, MD, Nolan Dang, MD, Daniel Q.Huang, MD, Ramsey Cheung, MD, Mindie H.
In this study, we used a national database that includes laboratory data in addition to medical and pharmacy claims data to assess the current real-world situation of chronic HBV infection care in the US. Among the 12,608 patients with chronic HBV, infection included in our study, 52.3% never had a complete laboratory and only 73% had adequate evaluation. Among those who were treatment eligible by AASLD or EASL guidelines, only 60.4% and 54.3% received treatment within 12 months, respectively
Surveillance of patients with cirrhosis remains suboptimal in the United States
Yee Hui Yeo, Jungyun Hwang, Donghak Jeong, Nolan Dang, Leslie Y. Kam, Linda Henry, Haesuk Park, Ramsey Cheung, Mindie H. Nguyen
Regular monitoring/surveillance for livercomplications is crucial to reduce morbidity and mortality in patients with cirrhosis. Recommendations from professional societies are available but adherence is not well studied, especially outside of academic centers. We aimed to determine the frequencies and factors associated with laboratory monitoring, and hepatocellular carcinoma (HCC) and esophageal varices (EV) surveillance in patients with cirrhosis.
Fatty Liver Index and Development of Cardiovascular Disease: Findings from the UK BiobankA population-based US study of hepatitis C diagnosis rate
Biyao Zou, Yee Hui Yeo, Ramsey Cheung, Erik Ingelsson, Mindie H. Nguyen
Fatty liver index not only predicts NAFLD diagnosis, but also indicates baseline and future development of cardiovascular disease on long-term follow-up across weight categories and fatty liver index spectrum. These findings can inform clinicians and other stakeholders on cardiovascular disease management and preventive efforts. Patients with high fatty liver index should be counseled on the increased future risk of developing cardiovascular disease.
A population-based US study of hepatitis C diagnosis rate
Yee Hui Yeo, Leslie Y. Kam, Michael H. Le, Donghak Jeong, Nolan Dang, Linda Henry,Ramsey Cheung and Mindie H. Nguyen
Hepatitis C virus (HCV) infection is a leading cause of hepatocellular carcinoma (HCC) and liver-related deathglobally [1,2]. In late 2013 and early 2014, new medications [all-oral interferon-free, direct-acting antiviralagents (DAAs)] were approved for treatment and cure of HCV with high efficacy [3,4].